TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04895579
Drug: Copanlisib
Normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Copanlisib will be delivered at various doses (30-60mg/kg) via IV infusion at days 1 and 15 every 28 days.
Study: NCT05004610
Drug: Sodium Lactate Solution
Normalized name: sodium lactate Injectable Solution
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuous intravenous infusion of molar sodium lactate
Study: NCT02119728
Drug: HPPH
Normalized name: HPPH
DrugBank: 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (DB15243)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo photodynamic therapy with HPPH
Study: NCT06134479
Drug: 150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Day 2 or 3 of the menstrual cycle, a first subcutaneous (SC) injection of corifollitropin alfa (CFA) (Elonva®) 150μg will be administered (stimulation day 1) and a second SC injection of corifollitropin alfa (Elonva®) 100 μg will be administrated on SD 5. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
Study: NCT06134479
Drug: 150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Day 2 or 3 of the menstrual cycle, a single subcutaneous (SC) injection of corifollitropin alfa (Elonva®) 150μg will be administered (SD 1) and from Day 8 of stimulation a daily SC dose of rFSH (Puregon®) 200IU/day up to the day of Triptorelin (Decapeptyl®) 0.2 mg administration. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
Study: NCT06136741
Drug: Rezpegaldesleukin
Normalized name: Rezpegaldesleukin
DrugBank: Rezpegaldesleukin (DB18992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous
Study: NCT05419011
Drug: Nogapendekin Alfa
Normalized name: Nogapendekin alfa
DrugBank: Nogapendekin alfa (DB18740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given nogapendekin alfa inbakicept (N-803) SC
Study: NCT05518903
Drug: Gallium Ga 68 FAPi-46
Normalized name: Gallium Ga 68 FAPi-46
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04947553
Drug: AXS-05 (dextromethorphan-bupropion)
Normalized name: AX
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AXS-05 tablets, taken twice daily
Study: NCT04906213
Drug: Empagliflozin10Mg Tab
Normalized name: Empagliflozin Tablets
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin10 Mg daily or placebo daily for 18 months
Study: NCT05944809
Drug: rhTPO
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment options:~Radiotherapy: 95% planning target volume （planning target volume，PTV） ≥45Gy(without simultaneous boost).~Concurrent chemotherapy:~Weekly regimen: paclitaxel 50mg/m2 d1, nedaplatin/cisplatin 25 mg/m2d1, a total of 5 cycles.~Three weeks regimen: paclitaxel 135-175mg/m2 d1, nedaplatin/cisplatin 80mg/m2, a total of 2 cycles.~The active bone marrow was determined by magnetic resonance（magnetic resonance，MR）, and the dose limits are: V5\<95%,V10\<85%,V20\<60%，V30\<40%；95%PTV\>45Gy.~rhTPO，15000U ih. qw(during the radiotherapy course)
Study: NCT05035862
Drug: Albuterol Sulfate
Normalized name: Albuterol Sulfate
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who experience symptoms of cough, dyspnea, chest tightness or wheezing will initiate use of albuterol (2 inhalations, 90 mcg/actuation) by metered dose inhaler (MDI) every 20 minutes for up to 1 hour and then every 4 hours if necessary.
Study: NCT05035862
Drug: Interferon gamma-primed mesenchymal stromal cells (MSCs)
Normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNγ-primed bone marrow MSCs at a dose level of 2x106 cells/kg and a dose level of 5x106 cells/kg
Study: NCT05035862
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone is recommended if the participant uses more than 12 inhalations of albuterol in 24 hours (excluding preventive use before exercise), or if the patient has ongoing symptoms for 48 hours or longer. The recommended prednisone dose for acute exacerbations is 2 mg/kg/day (maximum 60 mg) as a single dose for two days followed by 1 mg/kg/day (maximum 30 mg) as a single dose for two days. All administered doses will be rounded down to the nearest 10 mg.
Study: NCT06243458
Drug: RVU120 (SEL120)
Normalized name: SEL120-34A free base
DrugBank: SEL120-34A free base (DB18107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVU120 will be taken orally every other day (q.o.d). in a 21-day treatment cycle. Doses of RVU120 will be administered from day 1 to day 13 (total of 7 doses per cycle).
Study: NCT04880278
Drug: Nabilone
Normalized name: Nabilone
DrugBank: Nabilone (DB00486)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half of the participants (30 individuals) will receive nabilone 1mg. Nabilone will be placed in opaque capsules with dextrose filler and administered by mouth only once (around 120 minutes prior to fMRI scanning).
Study: NCT05720117
Drug: PYX-201
Normalized name: PYX-201
DrugBank: PYX-201 (DB18382)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05650411
Drug: Conventional DAPT
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 to 12 months of DAPT combining aspirin (≥75 mg od) and a P2Y12 inhibitor (clopidogrel 75 mg od, ticagrelor 90 mg bd, prasugrel 5 or 10 mg od at the discretion of the investigator) followed by aspirin SAPT.
Study: NCT05361447
Drug: Diazepam
Normalized name: Diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg twice daily oral for 1 week and then increase to 10 mg twice daily oral
Study: NCT05418972
Drug: Relatlimab and nivolumab fixed dose combination (FDC)
Normalized name: nivolumab and relatlimab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lymphocyte activation gene-3 (LAG-3) and programmed death-1 (PD-1) are two distinct inhibitory immune checkpoints that are often co-expressed on tumor-infiltrating lymphocytes, thus contributing to tumor-mediated T-cell exhaustion. The combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) results in increased T-cell activation compared to the activity of either antibody alone.
Study: NCT05737615
Drug: 64Cu-Tz-SarAr
Normalized name: 64Cu-dotatate
DrugBank: Copper oxodotreotide Cu-64 (DB15873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On study day 0, a single slow infusion of hu5B1-TCO will be administered intravenously. Subsequently, either 3 days (n = 3) or 5 days (n = 3) later, a single slow infusion of 64Cu-Tz-SarAr will be administered intravenously.
Study: NCT05222516
Drug: Broncho-Vaxom
Normalized name: Broncho-Vaxom
DrugBank: OM85 (DB16533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of Broncho-Vaxom 3.5mg capsules
Study: NCT05556512
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00000799
Drug: Cidofovir
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000799
Drug: Probenecid
Normalized name: Probenecid
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06199791
Drug: Lamotrigine 100 MG
Normalized name: lamotrigine 100 MG
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets
Study: NCT06241118
Drug: Amlitelimab
Normalized name: Amlitelimab
DrugBank: Amlitelimab (DB18835)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Study: NCT06241118
Drug: Topical tacrolimus or pimecrolimus
Normalized name: pimecrolimus Topical Cream
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Various Topical formulation Route of administration: Topical
Study: NCT05032157
Drug: LOU064 (open-label)
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOU064 (open-label) active treatment
Study: NCT05193227
Drug: ST-01
Normalized name: CE-VST-01-JC
DrugBank: CE-VST01-JC (DB17190)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of up to 8 mL ST-01 (70 mg/mL lidocaine)
Study: NCT05193227
Drug: Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of up to 3 mg/kg bupivacaine hydrochloride injection (0.25%) or up to 4.5mg/kg lidocaine hydrochloride injection (0.5-1%)
Study: NCT06782048
Drug: Pyrvinium
Normalized name: pyrvinium
DrugBank: Pyrvinium (DB06816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive pyrvinium (2 mg/kg/day) by mouth once each day for a total of 14 days.
Study: NCT06781086
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 3 cycles of neoadjuvant treatment with Nimotuzumab (400 mg on days 1, 8, and 15 of a 21-day cycle), followed by surgery and 5 cycles of adjuvant Nimotuzumab (400 mg on days 1, 8, and 15 of a 21-day cycle).
Study: NCT06218290
Drug: Oxylanthanum Carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phosphate Binder to Reduce Hyperphosphatemia
Study: NCT05332340
Drug: BZ371A
Normalized name: BZ371A
DrugBank: BZ371A (DB18101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose topical administration of 1.5 mL with a concentration of 5 mg/mL of BZ371A.
Study: NCT06737406
Drug: Topical 0.005% calcipotriol ointment
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.005% calcipotriol ointment twice daily for 21 days on the affected area (palmoplatar)
Study: NCT05138575
Drug: Empagliflozin + Potassium Chloride
Normalized name: Empagliflozin
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle.~KCl is an active control.
Study: NCT05138575
Drug: Empagliflozin + Potassium Nitrate
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin + KNO3 is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle, as well as increase skeletal muscle perfusion during exercise.
Study: NCT05138575
Drug: Potassium Chloride + Placebo for Empagliflozin
Normalized name: potassium chloride Powder for Oral Solution
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active control.
Study: NCT05110157
Drug: Valbenazine
Normalized name: Valbenazine
DrugBank: Valbenazine (DB11915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT04670081
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg, p.o.
Study: NCT04670081
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg, p.o.
Study: NCT06738368
Drug: Asparaginase Erwinia chrysanthemi
Normalized name: Asparaginase Erwinia chrysanthemi
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IM
Study: NCT06738368
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given CIV
Study: NCT06738368
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06738368
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given CIV
Study: NCT06587685
Drug: PG-011Gel
Normalized name: PG
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice daily for 52 weeks or 44 weeks
Study: NCT05306873
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily~Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening~Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily
Study: NCT05306873
Drug: Voclosporin
Normalized name: Voclosporin
DrugBank: Voclosporin (DB11693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weeks 1-24: 23.7 mg Voclosporin (3 x 7.9 capsules) twice daily
Study: NCT05306873
Drug: Placebo for Voclosporin
DrugBank: Voclosporin (DB11693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weeks 1-24: 23.7 mg Placebo for Voclosporin (3 x 7.9 capsules) twice daily
Study: NCT05306873
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stage 3 Dosing:~Participants who received placebo MMF in Stage 2:~* Week 1: Participants will receive 500mg MMF plus matching placebo for MMF (to appear like a 1000mg dose) twice daily~* Week 2: Participants will receive 500mg plus matching placebo for MMF (to appear like a 1000mg dose) and 1000mg in divided doses~* Weeks 3-24: 1000mg MMF twice daily~Participants who received MMF in Stage 2~• Week 1-24: 1000mg MMF twice daily
Study: NCT05419583
Drug: Antiplatelet Drug (Aspirin or Statin)
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy for coronary artery disease
Study: NCT05356377
Drug: Pegvaliase-Pqpz
Normalized name: pegvaliase-pqpz
DrugBank: Pegvaliase (DB12839)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will have been prescribed pegvaliase-pqpz (Palynziq) by their primary metabolic care providers as part of their standard care. \[Note that prescription and standard care are independent of the present study.\]
Study: NCT05953389
Drug: Pitolisant
Normalized name: pitolisant
DrugBank: Pitolisant (DB11642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: histamine H3 receptor antagonist/inverse agonist
Study: NCT06498583
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25 % ropivacaine ( 0.5ml / kg )
Study: NCT05487807
Drug: Nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will be receiving nicotine therapy
Study: NCT06739928
Drug: Irinotecan liposome (II) combined with adebrelimab and carboplatin
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan liposome (II) + adebrelimab + carboplatin
Study: NCT06739928
Drug: etoposide combined with adebrelimab and carboplatin
Normalized name: Carboplatin
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: etoposide + adebrelimab + carboplatin
Study: NCT05206201
Drug: ZY19489 Capsule
Normalized name: ZY19489
DrugBank: ZY19489 (DB18062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two part study with single and multiple dose
Study: NCT05707403
Drug: BI 1015550
Normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment T
Study: NCT05722327
Drug: MRTX849
Normalized name: KRAS G12C inhibitor MRTX849
DrugBank: Adagrasib (DB15568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO (mouth)
Study: NCT05722327
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV (vein)
Study: NCT05722327
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV (vein)
Study: NCT05176314
Drug: Pirtobrutinib
Normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Orally.
Study: NCT05728489
Drug: BI 765250
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 765250
Study: NCT05556798
Drug: Belantamab Mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin will be administered via IV infusion in an outpatient setting on Day 1 of Cycles 1-3. Treatment with belantamab mafodotin will be given at an initial dose of 1.0 mg/kg. The study will have a 3+3 dose escalation design for belantamab mafodotin. Belantamab mafodotin dose levels are 1.0 mg/kg, 1.4 mg/kg, and 1.9 mg/kg
Study: NCT05556798
Drug: Nirogacestat
Normalized name: NIROGACESTAT
DrugBank: Nirogacestat (DB12005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:1 randomization between nirogacestat 100mg BID or 100 mg QD during the 4 day run-in period. Treatment with nirogacestat will be 100mg BID continuously during each cycle for all subjects.
Study: NCT05556798
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After the 4-day run-in period, all patients will receive nirogacestat in combination with belantamab, mafodotin and pomalidomide. Pomalidomide was added for day 1-14 for cycle 1-3 and day 1-14 and day 21-35 for C4+.
Study: NCT05807711
Drug: L-Methyl Folate and methylcobalamine
Normalized name: L-Methyl Dopa
DrugBank: Cobalamin (DB14098)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary supplement labeled to contain methylfolate 800 micrograms and methylcobalamine 1000 micrograms
Study: NCT05733715
Drug: Pembrolizumab infusion
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg/ 4mL on Day 1 of each 3- or 6- week cycle (one 3 wk cycle; up to eight 6 wk cycles)
Study: NCT05733715
Drug: Lenvatinib tablet
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10mg and 4mg daily for 21 days
Study: NCT05097599
Drug: lorlatinib
Normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This arm of the Strata PATH trial will assess the clinical benefit of Lorbrena® (lorlatinib) in ALK and ROS1 gene fusion positive solid tumors, as detected by Strata testing, with the exception of NSCLC.
Study: NCT05097599
Drug: encorafenib + binimetinib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This arm of the Strata PATH trial will assess the clinical benefit of Braftovi® (encorafenib) + Mektovi® (binimetinib) in BRAF p.v600X mutated solid tumors, as detected by Strata testing, with the exception of melanoma and colorectal cancer.
Study: NCT05097599
Drug: talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This arm of the Strata PATH trial will assess the clinical benefit of Talzenna® (talazoparib) in patients with advanced solid tumors harboring deep deletions or deleterious mutations with LOH in BRCA1/2 and PALB2, as detected by Strata testing, excluding HER2 negative breast cancer.
Study: NCT04853368
Drug: ABBV-576
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT04853368
Drug: Galicaftor
Normalized name: Galicaftor
DrugBank: Galicaftor (DB14894)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT04853368
Drug: Navocaftor
Normalized name: Navocaftor
DrugBank: Navocaftor (DB19039)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT04853368
Drug: ABBV-119
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT05751421
Drug: Bupivacaine HCl 0.5% Injectable Solution
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: adductor canal block will be performed using bupivacaine before surgery
Study: NCT02738073
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05097599
Drug: sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: This arm of the Strata PATH trial will assess the clinical benefit of Trodelvy® (sacituzumab govitecan) in patients with advanced solid tumors and are Trop2 Treatment Response Score High (Trop2 TRS-H), as detected by Strata testing, excluding triple negative breast cancer, hormone receptor positive/ human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer, metastatic urothelial cancer, non-small cell lung (NSCLC) cancer, small cell lung cancer (SCLC), head and neck cancer, colorectal cancer (CRC), and endometrial cancer.
Study: NCT05097599
Drug: axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This arm of the Strata PATH trial will assess the clinical benefit of Inlyta® (axitinib) in patients with advanced solid tumors and are Angiogensis Inhibitor Treatment Response Score High (Angio TRS-H), as detected by Strata testing, excluding renal cell carcinoma, alveolar soft part sarcoma, and solitary fibrous tumors.
Study: NCT05097599
Drug: Fam-Trastuzumab Deruxtecan-Nxki
Normalized name: fam-trastuzumab deruxtecan-nxki
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This arm of the Strata PATH trial will assess the clinical benefit of Enhertu ® in patients with advanced solid tumors with Her2 overexpression
Study: NCT05097599
Drug: enfortumab vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This arm of the Strata PATH trial will assess the clinical benefit of Padcev® in patients with advanced solid tumors with nectin-4 overexpression
Study: NCT06116409
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine was used for postoperative analgesia block.